Oncology (all articles)
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.
11 Sep, 2022 | 22:50h | UTCAASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma – Hepatology
RCT | Rezvilutamide vs. Bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer.
11 Sep, 2022 | 22:52h | UTCCommentaries:
Treatment options for metastatic hormone-sensitive prostate cancer – The Lancet Oncology
Rezvilutamide benefits shown in metastatic hormone-sensitive prostate cancer – medwire News
Commentary on Twitter
In a preplanned interim analysis of the phase III CHART trial in pts with high-volume mHSPC, rezvilutamide +ADT improve PFS (HR 0.44, 95% CI 0.33–0·.8; P<0.0001) & OS (HR 0.58, 95% CI 0.44–0.77]; P=0.0001) compared with bicalutamide + ADT: https://t.co/42IVnDUxfH #PCSM #uroonc
— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022
Guidelines for cancer treatment during pregnancy: ethics-related content evolution and implications for clinicians.
11 Sep, 2022 | 22:47h | UTC
Screening for high-risk human papillomavirus using passive, self-collected menstrual blood.
11 Sep, 2022 | 22:41h | UTCCommentary: Pap smears, be gone? Using menstrual blood to detect HPV – Stanford Medicine
Commentary on Twitter
FREE: Screening for High-Risk Human Papillomavirus Using Passive, Self-Collected Menstrual Blood #obgyn #HPV #GYN https://t.co/zLno2ab605 pic.twitter.com/mfPGjlTLdD
— The Green Journal (@greenjrnl) September 1, 2022
RCT | Adjuvant atezolizumab fails to improve outcomes in patients with renal cell carcinoma at increased risk of recurrence following resection.
11 Sep, 2022 | 22:28h | UTCAdjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentaries:
Adjuvant atezolizumab falls short in renal cell carcinoma – Urology Times
IMmotion010 does not support adjuvant atezolizumab in intermediate-, high-risk RCC – medwire News
Commentary from the author on Twitter (thread – click for more)
Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) https://t.co/F5Y5HyNaxY pic.twitter.com/klAYWAQVwV
— Sumanta K. Pal, MD, FASCO (@montypal) September 10, 2022
Phase 2 RCT | Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease.
11 Sep, 2022 | 22:25h | UTC
RCT | Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation.
11 Sep, 2022 | 22:21h | UTC
Large study unravels the risk factors for heart failure among childhood cancer survivors.
11 Sep, 2022 | 22:22h | UTC
RCT | Ripretinib vs. Sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib.
8 Sep, 2022 | 14:24h | UTC
Commentary on Twitter
👀 INTRIGUE Trial: Ipretinib not superior to sunitinib but demonstrates longest median progression free survival ever in advanced #GastrointestinalStromalTumor ➡️ https://t.co/aUNdvXaQcH #GIST #scmsm @seppobauer pic.twitter.com/pPfph6A8Lr
— Journal of Clinical Oncology (@JCO_ASCO) August 24, 2022
Cohort Study | Fertility preservation procedures appear to be safe at the time of breast cancer diagnosis.
7 Sep, 2022 | 12:31h | UTCNews Release: Fertility preservation measures do not appear to increase the risk of breast cancer recurrence – Karolinska Institutet
Noninferiority RCT | Induction chemotherapy regimen of docetaxel plus cisplatin vs. docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.
6 Sep, 2022 | 14:29h | UTC
RCT | Anatomical segmentectomy vs. standard lobectomy for non-small cell lung cancer up to 2 cm.
6 Sep, 2022 | 14:28h | UTCRelated:
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Single-arm, phase 2 study | Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
6 Sep, 2022 | 14:24h | UTCGalunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Review | Cardiovascular complications of immune checkpoint inhibitors for cancer.
6 Sep, 2022 | 14:20h | UTCCardiovascular complications of immune checkpoint inhibitors for cancer – European Heart Journal
Related:
Cardiotoxicity of immune checkpoint inhibitors – ESMO Open
Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature
Commentary on Twitter
Must read state-of-the-art review: Cardiovascular complications of immune checkpoint inhibitors for cancer https://t.co/0lr7g6s8g0
#EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/jORaTzP7GD— European Society of Cardiology Journals (@ESC_Journals) September 5, 2022
Opinion | People with terminal cancer need to know they are dying. Doctors shouldn’t withhold that information.
5 Sep, 2022 | 14:35h | UTC
5-year follow-up of a RCT | Five-year outcomes of FOLFIRINOX vs. Gemcitabine as adjuvant therapy for pancreatic cancer.
5 Sep, 2022 | 14:26h | UTCFive-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Updated 5-year results of the Unicancer PRODIGE 24/CCTG PA6 trial confirmed the significant improvement in all outcomes, including overall survival, with mFOLFIRINOX regimen compared to gemcitabine in adjuvant setting for pts w #pancreaticcancer. https://t.co/rCFntho0f1 #GICSM pic.twitter.com/VAVBD7o6kc
— JAMA Oncology (@JAMAOnc) September 1, 2022
Review | The prevention and treatment of nausea and vomiting during tumor therapy.
5 Sep, 2022 | 14:23h | UTCThe Prevention and Treatment of Nausea and Vomiting During Tumor Therapy – Deutsches Ärzteblatt International
Related:
SEOM clinical guideline emesis (2021) – Clinical and Translational Oncology
Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes – Drugs & Aging (if the link is paywalled, try this one)
30-month follow-up analysis of a RCT | Pembrolizumab vs. placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma.
5 Sep, 2022 | 14:20h | UTCInvited Commentary: Adjuvant immunotherapy for renal cell carcinoma – The Lancet Oncology
Original Article: Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma – New England Journal of Medicine
RCT | Telaglenastat failed to improve the efficacy of Cabozantinib in patients with advanced renal cell carcinoma.
5 Sep, 2022 | 14:19h | UTCEfficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary on Twitter
https://twitter.com/JAMAOnc/status/1565368902674178048
Systematic Review | Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
5 Sep, 2022 | 14:13h | UTC
Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management.
2 Sep, 2022 | 13:02h | UTC
3-year outcomes of a RCT | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma.
2 Sep, 2022 | 13:04h | UTCOriginal Study: Randomized trial: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score
2 Sep, 2022 | 13:03h | UTC
Guideline | Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer.
1 Sep, 2022 | 11:53h | UTC
Single-arm phase 2 study | Neoadjuvant Nivolumab plus Ipilimumab and Adjuvant Nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma.
1 Sep, 2022 | 11:47h | UTC